http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2001007774-A1

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-962
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54313
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543
filingDate 1997-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c2f69a1e9adcf8dfed3ed2a7946ca1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53096004a43fe6cea5edb00279971a22
publicationDate 2001-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2001007774-A1
titleOfInvention Immunoassay
abstract Disclosed herein is an immunoassay comprising reacting an immobilized antibody obtained by holding an antibody, which recognizes a part of an objective antigen of determination, on insoluble carrier particles with an antigen in a test specimen, then reacting a free antibody, which recognizes an antigen site different from that recognized by the immobilized antibody, with the antigen; or reacting a free antibody, which recognizes a part of an objective antigen of determination, with an antigen in a test specimen, then reacting an immobilized antibody obtained by holding an antibody, which recognizes an antigen site different from that recognized by the free antibody, on insoluble carrier particles with the antigen, and optically determining the degree of a change in agglutination occurred by the reaction. n The immunoassay of the invention has advantages that it has high specificity and is simple and low in cost, and with respect to the antibodies used, insofar as one of the immobilized antibody and the free antibody has high specificity for the objective antigen of determination, the other antibody does not need to have strict specificity and may have some cross-reactivity.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009117668-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11378577-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11237157-B2
priorityDate 1996-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16161315
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399536
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226414067
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411934
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21226141
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16186314
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5920
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22808555
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5819
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127463032
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396684
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421303
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129742115
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399670
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID853
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421304

Total number of triples: 31.